Researchers discover additional targets for existing drugs used to treat a specific melanoma

 

A set of targeted cancer drugs, known as BRAF and MEK inhibitors, have proven to be beneficial for some metastatic melanoma patients whose tumours include a specific mutation in the BRAF gene, known as V600E. A recent study conducted in the lab of Dr. Peter Siegel at McGill University’s Goodman Cancer Research Centre suggests that these same drugs may prove beneficial for a broader range of cancer patients.

Classified as: Goodman Cancer Research Centre, Rosalind and Morris Cancer Research Centre
Published on: 4 Oct 2018
Back to top